1. EGFR Inhibitors in Advanced NSCLC: Who, When, and Why?

3. EGFR Mutations and Testing of Lung Cancer Tumors

4. First-Line Use of EGFR TKIs

5. EURTAC: Interim Analysis of OS in Intent-to-Treat Population

6. First-Line Use of EGFR TKIs

7. EGFR TKI Maintenance Regimens Used in Switch Trials

9. TORCH Trial Design

11. BR.21: Erlotinib Beyond the First-Line

12. EGFR TKIs vs Chemotherapy in Previously Treated Unselected Patients

13. TAILOR Study Design

15. SATURN Study Design

18. SATURN: PFS Stratified by Biomarker Status

19. ATLAS Study Design

20. ATLAS: PFS

23. OS Data for MetMAb and Erlotinib in Key Subpopulations

24. Resistance to EGFR TKIs